Acute Myeloid Leukemia (AML) with Erythroid Predominance Exhibits Clinical and Molecular Characteristics that Differ from Other Types of AML

Zuo, Zhuang; Medeiros, L. Jeffrey; Zhao, Chen; Bueso‐Ramos, Carlos E.; Luthra, Rajyalakshmi; Wang, Sa A.

doi:10.1371/journal.pone.0041485

Cited by 25 publications

(24 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This change was based on the close biologic relationship of erythroid/myeloid type acute erythroid leukemia to MDS in terms of its clinical presentation, morphologic features, and genetic abnormalities, as well as the low reproducibility of nonerythroid blast counts and an attempt to achieve uniformity in expressing blast percentages across all myeloid neoplasms. [102][103][104][105][106] Cases with $50% or more erythroid cells and $20% total myeloblasts usually meet criteria for AML with myelodysplasia-related changes and should be diagnosed as such; cases with $20% total myeloblasts not meeting criteria for AML with myelodysplasia-related changes or AML with recurrent genetic abnormalities should be categorized as 1 of the other subtypes of AML, NOS. Pure erythroid leukemia remains as an AML, NOS subtype and is now the only type of acute erythroid leukemia.…”

Section: Aml Not Otherwise Specifiedmentioning

confidence: 99%

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

Arber

Orazi

Hasserjian

et al. 2016

Blood

8,279

7,810

View full text Add to dashboard Cite

The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues was last updated in 2008. Since then, there have been numerous advances in the identification of unique biomarkers associated with some myeloid neoplasms and acute leukemias, largely derived from gene expression analysis and next-generation sequencing that can significantly improve the diagnostic criteria as well as the prognostic relevance of entities currently included in the WHO classification and that also suggest new entities that should be added. Therefore, there is a clear need for a revision to the current classification. The revisions to the categories of myeloid neoplasms and acute leukemia will be published in a monograph in 2016 and reflect a consensus of opinion of hematopathologists, hematologists, oncologists, and geneticists. The 2016 edition represents a revision of the prior classification rather than an entirely new classification and attempts to incorporate new clinical, prognostic, morphologic, immunophenotypic, and genetic data that have emerged since the last edition. The major changes in the classification and their rationale are presented here.

show abstract

Section: Aml Not Otherwise Specifiedmentioning

confidence: 99%

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

Arber

Orazi

Hasserjian

et al. 2016

Blood

8,279

7,810

View full text Add to dashboard Cite

show abstract

“…[34][35][36] Moreover, the erythroid/myeloid type of acute myeloid leukemia has a mutation profile that is more similar to MDS than to de novo AML. 37,38 For these reasons, the WHO has proposed to eliminate the non-erythroid blast cell count rule and to move such cases out of the category of acute myeloid leukemia and into the appropriate MDS category based on the absolute blast cell count. For example, a case with 60% bone marrow erythroid precursors and 11% myeloblasts would now be classified as MDS with excess blasts-2 (MDS-EB2).…”

Section: Mds-related Changes In Other Who Categoriesmentioning

confidence: 99%

Reclassifying myelodysplastic syndromes: what's where in the new WHO and why

Arber

Hasserjian

2015

Hematology

View full text Add to dashboard Cite

A revision to the 4th edition of the WHO Classification of myelodysplastic syndromes (MDSs), originally published in 2008, is expected in mid-2016. Based on recommendations of a Clinical Advisory Committee, the revision will aim to incorporate new discoveries in MDS that impact existing disease categories. Although the basic diagnostic principles of the WHO classification remain unchanged, several changes to the classification are proposed. All revisions are considered preliminary until the actual publication of the monograph and online document. Proposals for change include abandoning the routine use of "refractory anemia/cytopenia" in the various disease names, including the prognostic significance of gene mutations in MDS, revising the diagnostic criteria for MDS entities with ring sideroblasts based on the detection of SF3B1 mutations, modifying the cytogenetic criteria for MDS with isolated del(5q), reclassifying most cases of the erythroid/myeloid type of acute erythroleukemia, and recognizing the familial link in some cases of MDS. This review will provide details of the major proposed changes as well as rationale for the revisions. Learning Objective• Understand proposed changes to the WHO classification of myelodysplastic syndromes

show abstract

“…Similarly, a slight change of erythroid percentage (≥50% versus <50%) can alter the diagnosis, often as a result of fluctuations from therapy, nutritional deficiencies (iron, B12, foliate), erythropoietin (EPO) administration, or inter/intra observer variation in counting cells. For these reasons, some experts have suggested that erythroleukemia is not a distinct entity and should be merged into the MDS category based on evidence that they are biologically related diseases: morphologic dysplasia is a common feature of both MDS and erythroleukemia; erythroleukemia often represents disease progression from a prior MDS; and, the genetic abnormalities in erythroleukemia are more similar to those seen in MDS than de novo AML, including common TP53 mutations and rare FLT3 and NPM1 mutations . In response, the recently published 2016 update of the WHO classification of myeloid neoplasms has eliminated the 2008 WHO classification scheme for erythroleukemia.…”

Section: Introductionmentioning

confidence: 99%

Pure erythroid leukemia

Wang

Medeiros

et al. 2017

American J Hematol

Self Cite

View full text Add to dashboard Cite

The category of acute erythroid leukemia was significantly revised in the recently published 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms. In the previous 2008 WHO classification, acute erythroid leukemia was categorized into two subtypes: erythroleukemia and pure erythroid leukemia (PEL), whereas in the 2016 WHO update, erythroleukemia was merged into myelodysplastic syndrome, and PEL becomes the only type of acute erythroid leukemia. PEL is a rare and aggressive form of acute leukemia whose biology remains poorly characterized. In this review, we discuss the clinicopathologic features, diagnosis, putative pathogenesis, and molecular biology of PEL, with an overview of novel concepts and future directions in this area.wileyonlinelibrary.com/journal/ajh Am J Hematol. 2017;92:292-296

show abstract

Acute Myeloid Leukemia (AML) with Erythroid Predominance Exhibits Clinical and Molecular Characteristics that Differ from Other Types of AML

Cited by 25 publications

References 27 publications

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

Reclassifying myelodysplastic syndromes: what's where in the new WHO and why

Pure erythroid leukemia

Contact Info

Product

Resources

About